WallStreetZenWallStreetZen

NYSE: CTLT
Catalent Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

CTLT past earnings growth

How has CTLT's earnings growth performed historically?
Company
-31%
Industry
5.91%
Market
28.69%
CTLT's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
CTLT's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Market Performance
CTLT's earnings growth is slowing... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

CTLT past revenue growth

How has CTLT's revenue growth performed historically?
Company
6.11%
Industry
255.23%
Market
17.24%
CTLT's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
CTLT's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Market Performance
CTLT's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

CTLT earnings and revenue history

Current Revenue
$4.8B
Current Earnings
$409.0M
Current Profit Margin
8.6%

CTLT Return on Equity

Current Company
8.6%
Current Industry
9.1%
Current Market
188%
CTLT's Return on Equity (8.6%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when CTLT announces earnings.

CTLT Return on Assets

Current Company
3.9%
Current Industry
4.4%
CTLT is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

CTLT Return on Capital Employed

Current Company
6.74%
Current Industry
10.2%
CTLT has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

CTLT vs Pharmaceutical Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
CTLT$4.76B$1.05B$409.00M+15.65%+31.38%
VTRS$16.26B$6.43B$2.08B+6.43%+5.64%
TEVA$14.93B-$717.00M-$2.35B-7.34%N/A
RDY$2.73B$575.00M$300.61M+5.35%+10.90%
PRGO$4.45B$345.80M-$140.60M-2.09%N/A
View Top Pharmaceutical Stocks

CTLT earnings dates

Next earnings date
May 1, 2023

Catalent Earnings & Revenue FAQ

What were CTLT's earnings last quarter?

On Invalid Date, Catalent (NYSE: CTLT) reported Q4 2022 earnings per share (EPS) of $0.45, up 15.09% year over year. Total Catalent earnings for the quarter were $81.00 million. In the same quarter last year, Catalent's earnings per share (EPS) was $0.53.

If you're new to stock investing, here's how to buy Catalent stock.

What was CTLT's earnings growth in the past year?

As of Q2 2023, Catalent's earnings has grown -31% year over year. This is 36.92 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry earnings growth rate of 5.91%. Catalent's earnings in the past year totalled $409.00 million.

What is CTLT's earnings date?

Catalent's earnings date is Invalid Date. Add CTLT to your watchlist to be reminded of CTLT's next earnings announcement.

What was CTLT's revenue last quarter?

On Invalid Date, Catalent (NYSE: CTLT) reported Q4 2022 revenue of $1.15 billion up 5.59% year over year. In the same quarter last year, Catalent's revenue was $1.22 billion.

What was CTLT's revenue growth in the past year?

As of Q2 2023, Catalent's revenue has grown 6.11% year over year. This is 249.12 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 255.23%. Catalent's revenue in the past year totalled $4.76 billion.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.